Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis.

Ovejero-Benito MC, Muñoz-Aceituno E, Sabador D, Reolid A, Llamas-Velasco M, Prieto-Pérez R, Abad-Santos F, Daudén E.

J Eur Acad Dermatol Venereol. 2020 Feb 11. doi: 10.1111/jdv.16256. [Epub ahead of print]

PMID:
32043647
2.

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, Ortí G, Holgado-Martín E, García-Vidal C, Vizcaya-Morales C, Martín-Vázquez V, González-Gay MÁ.

Autoimmun Rev. 2020 Jan;19(1):102429. doi: 10.1016/j.autrev.2019.102429. Epub 2019 Nov 15. Review.

3.

Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation.

Cibrian D, Castillo-González R, Fernández-Gallego N, de la Fuente H, Jorge I, Saiz ML, Punzón C, Ramírez-Huesca M, Vicente-Manzanares M, Fresno M, Daudén E, Fraga-Fernandez J, Vazquez J, Aragonés J, Sánchez-Madrid F.

J Allergy Clin Immunol. 2020 Jan;145(1):199-214.e11. doi: 10.1016/j.jaci.2019.09.025. Epub 2019 Oct 9.

4.

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.

Reolid A, Muñoz-Aceituno E, Rodríguez-Jiménez P, González-Rojano E, Llamas-Velasco M, Fraga J, Daudén E.

Int J Dermatol. 2020 Feb;59(2):197-206. doi: 10.1111/ijd.14658. Epub 2019 Oct 12.

PMID:
31605541
5.

Validation of an Optical Pencil Method to Estimate the Affected Body Surface Area in Psoriasis.

Reolid A, Servitje O, Ginarte M, Pérez-Ferriols A, Vélez A, Aragües M, Pereiro M, Sánchez-Carazo JL, Garrido J, Daudén E; Grupo de Trabajo de evaluación del Body Surface Area (BSA).

Actas Dermosifiliogr. 2019 Aug 28. pii: S0001-7310(19)30314-X. doi: 10.1016/j.ad.2019.07.002. [Epub ahead of print] English, Spanish.

PMID:
31472926
6.

Faziales follikulär-zystisches und kollagenes Hamartom: eine Variante der fibrösen Stirnplaque mit prominenter Zystenbildung?

Reolid A, Navarro R, Daudén E, Alonso-Cerezo MC, Fraga J, Llamas-Velasco M.

J Dtsch Dermatol Ges. 2019 Jul;17(7):738-741. doi: 10.1111/ddg.13867_g. No abstract available.

PMID:
31364308
7.

Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis.

Rodríguez-Jiménez P, Chicharro P, Llamas-Velasco M, Cibrian D, Trigo-Torres L, Vara A, Jiménez-Fernández M, Sevilla-Montero J, Calzada MJ, Sánchez-Madrid F, de la Fuente H, Daudén E.

Front Immunol. 2019 Jun 4;10:1268. doi: 10.3389/fimmu.2019.01268. eCollection 2019.

8.

Osteoporosis and Psoriasis.

Muñoz-Torres M, Aguado P, Daudén E, Carrascosa JM, Rivera R.

Actas Dermosifiliogr. 2019 Oct;110(8):642-652. doi: 10.1016/j.ad.2019.02.005. Epub 2019 May 28. English, Spanish.

PMID:
31151668
9.

Facial folliculocystic and collagen hamartoma: a variant of fibrous cephalic plaque with prominent cyst formation?

Reolid A, Navarro R, Daudén E, Alonso-Cerezo MC, Fraga J, Llamas-Velasco M.

J Dtsch Dermatol Ges. 2019 Jul;17(7):738-741. doi: 10.1111/ddg.13867. Epub 2019 May 30. No abstract available.

PMID:
31148377
10.

Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population.

Gonzalez-Cantero A, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cueva P, Gómez-García FJ, Belinchón I, Herrera-Ceballos E, Ruiz-Genao D, Ferrán M, Alsina M, Sánchez-Carazo JL, Baniandrés O, Sahuquillo-Torralba A, Rodriguez L, Vilar J, García C, Carrascosa JM, Llamas-Velasco M, Herrera-Acosta E, López-Estebaranz JL, Botella-Estrada R, Descalzo MA, García-Doval I; BIOBADADERM Study Group.

Br J Dermatol. 2019 Nov;181(5):1085-1087. doi: 10.1111/bjd.18164. Epub 2019 Aug 13. No abstract available.

PMID:
31127858
11.

Bilateral Facial Apocrine Fibrosing Hamartoma Mimicking Microcystic Adnexal Carcinoma.

Llamas-Velasco M, Fraga J, Schaller J, Requena L, Daudén E, Rütten A.

Am J Dermatopathol. 2019 Oct;41(10):767-770. doi: 10.1097/DAD.0000000000001433.

PMID:
31045870
12.

Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis.

de la Cueva Dobao P, Notario J, Ferrándiz C, López Estebaranz JL, Alarcón I, Sulleiro S, Borrás J, Daudén E, Carrascosa JM, Sánchez Carazo JL, Monte Boquet E, Puig L.

J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1214-1223. doi: 10.1111/jdv.15600. Epub 2019 Apr 29.

PMID:
31037770
13.

[Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain].

Puig L, Ruiz de Morales JG, Dauden E, Andreu JL, Cervera R, Adán A, Marsal S, Escobar C, Hinojosa J, Palau J, Arraiza A, Casado P, Codesido M, Pascual C, Saldaña R, Gil Á.

Rev Esp Salud Publica. 2019 Mar 25;93. pii: e201903013. Spanish.

14.

Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.

Puig L, Carrascosa JM, Daudén E, Sulleiro S, Guisado C.

J Dermatolog Treat. 2019 Jun 20:1-8. doi: 10.1080/09546634.2019.1597244. [Epub ahead of print]

PMID:
30888880
15.

Tuberculosis re-screening in psoriatic patients under continuous biological therapy. Does the treatment modify the tuberculin skin test response?

Chicharro P, Sánchez-Moya A, Rodríguez-Jiménez P, Llamas-Velasco M, Daudén E.

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):e295-e296. doi: 10.1111/jdv.15567. Epub 2019 Apr 15. No abstract available.

PMID:
30868677
16.

Trough (C0) and 2-hour postdose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis.

Herrero-Moyano M, Pedraz J, Muñoz-Aceituno E, Chicharro P, Reolid A, Lara S, Daudén E.

J Eur Acad Dermatol Venereol. 2019 May;33(5):e215-e217. doi: 10.1111/jdv.15481. Epub 2019 Mar 5. No abstract available.

PMID:
30735587
17.

Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit.

Alvaro-Gracia JM, Arredondo M, Daudén E, Meca-Lallana V, Morell A, Gisbert JP, Fernández-Jiménez G, García de Vicuña R, Aspa FJ, García de Yébenes MJ, Carmona L.

Reumatol Clin. 2019 Mar - Apr;15(2):63-68. doi: 10.1016/j.reuma.2018.11.008. Epub 2019 Jan 26. English, Spanish.

18.

Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis.

Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Fisas LH, Llamas-Velasco M, Prieto-Pérez R, Abad-Santos F, Daudén E.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e175-e177. doi: 10.1111/jdv.15431. Epub 2019 Feb 18. No abstract available.

PMID:
30653751
19.

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.

Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Fernández Nebro A, Muñoz-Fernández S, González CM, Roig D, Zarco P, Erra A, Rodríguez J, Castañeda S, Rubio E, Salvador G, Díaz-Torné C, Blanco R, Willisch Domínguez A, Mosquera JA, Vela P, Sánchez-Fernández SA, Corominas H, Ramírez J, de la Cueva P, Fonseca E, Fernández E, Puig L, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno D, Vanaclocha F, Herrera E, Blanco F, Fernández-Gutiérrez B, González A, Pérez-García C, Alperi-López M, Olivé Marques A, Martínez-Taboada V, González-Álvaro I, Sanmartí R, Tomás Roura C, García-Montero AC, Bonàs-Guarch S, Mercader JM, Torrents D, Codó L, Gelpí JL, López-Corbeto M, Pluma A, López-Lasanta M, Tortosa R, Palau N, Absher D, Myers R, Marsal S, Julià A.

Ann Rheum Dis. 2019 Mar;78(3). pii: e214158. doi: 10.1136/annrheumdis-2018-214158. Epub 2018 Dec 14.

PMID:
30552173
20.

Psoriasis and Depression: The Role of Inflammation.

González-Parra S, Daudén E.

Actas Dermosifiliogr. 2019 Jan - Feb;110(1):12-19. doi: 10.1016/j.ad.2018.05.009. Epub 2018 Dec 1. Review. English, Spanish.

PMID:
30509759
21.

Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study.

Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, Soria C, Belinchón I, de la Cueva P, Ferrán M, Carrascosa JM, Gómez FJ, Salgado L, Velasco M, Descalzo MÁ, García-Doval I, Daudén E; ; the BIOBADADERM Study Group and Psoriasis Group of the AEDV.

J Dermatolog Treat. 2019 Aug;30(5):461-465. doi: 10.1080/09546634.2018.1535690. Epub 2018 Nov 28.

PMID:
30307344
22.

Histone modifications associated with biological drug response in moderate-to-severe psoriasis.

Ovejero-Benito MC, Reolid A, Sánchez-Jiménez P, Saiz-Rodríguez M, Muñoz-Aceituno E, Llamas-Velasco M, Martín-Vilchez S, Cabaleiro T, Román M, Ochoa D, Daudén E, Abad-Santos F.

Exp Dermatol. 2018 Dec;27(12):1361-1371. doi: 10.1111/exd.13790.

PMID:
30260532
23.

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.

Herrero-Moyano M, Capusan TM, Martínez-Mera C, Llamas-Velasco M, Daudén E.

JAAD Case Rep. 2018 Sep 19;4(8):842-844. doi: 10.1016/j.jdcr.2018.03.016. eCollection 2018 Sep. No abstract available.

24.

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

Capusan TM, Herrero-Moyano M, Martínez-Mera CR, Freih-Fraih AW, Dauden E.

JAAD Case Rep. 2018 Jun 2;4(6):521-523. doi: 10.1016/j.jdcr.2018.04.015. eCollection 2018 Jul. No abstract available.

25.

Position statement for the management of comorbidities in psoriasis.

Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, Jodar E, Joven B, Lázaro P, Olveira A, Quintero J, Rivera R.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2058-2073. doi: 10.1111/jdv.15177. Epub 2018 Aug 14. Review.

PMID:
29992631
26.

Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.

Rodríguez-Jiménez P, Mir-Viladrich I, Chicharro P, Solano-López G, López-Longo FJ, Taxonera C, Sánchez-Martínez P, Martínez-Lacasa X, García-Gasalla M, Dorca J, Arias-Guillén M, García-García JM, Dauden E.

Actas Dermosifiliogr. 2018 Sep;109(7):584-601. doi: 10.1016/j.ad.2018.03.013. Epub 2018 Jun 2. English, Spanish.

PMID:
29871738
27.

Facial Calcinosis Cutis in a Woman with Paraneoplastic Dermatomyositis.

Herrero-Moyano M, Martínez-Mera C, García-García C, Dauden E.

Actas Dermosifiliogr. 2018 Oct;109(8):760-762. doi: 10.1016/j.ad.2017.11.004. Epub 2018 Mar 26. English, Spanish. No abstract available.

PMID:
29598989
28.

GATA3 staining in primary cutaneous apocrine cribriform carcinoma: Usefulness to differentiate it from breast cancer metastasis.

Llamas-Velasco M, Pérez-Gónzalez YC, Daudén E, Rütten A.

J Cutan Pathol. 2018 May;45(5):348-351. doi: 10.1111/cup.13124. Epub 2018 Mar 12.

PMID:
29431200
29.

Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.

Chicharro P, Paniagua A, Rodríguez-Jiménez P, Ibañes S, Cortina B, Riveiro J, Sampedro-Núñez MÁ, Fraga J, Marazuela M, Daudén E.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1887-1892. doi: 10.1111/jdv.14830. Epub 2018 Feb 14.

PMID:
29377286
30.

Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.

Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F.

Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.

PMID:
29192552
31.

Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study.

Descalzo MA, Carretero G, Ferrándiz C, Rivera R, Daudén E, Gómez-García FJ, de la Cueva P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Baniandrés O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Muñoz-Santos C, García-Doval I; Biobadaderm Study Group.

J Am Acad Dermatol. 2018 Apr;78(4):798-800. doi: 10.1016/j.jaad.2017.10.051. Epub 2017 Nov 13. No abstract available.

PMID:
29146129
32.

Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.

Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E.

Am J Clin Dermatol. 2018 Apr;19(2):209-222. doi: 10.1007/s40257-017-0322-9. Review.

PMID:
28921458
33.

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, Saiag P, Smith CH, Dauden E, de Jong EM, Feist E, Jobling R, Maccarone M, Mrowietz U, Papp KA, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Dressler C.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. Epub 2017 Sep 11. No abstract available.

PMID:
28895202
34.

Recommendations for the management of comorbidity in hidradenitis suppurativa.

Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, García-Campayo J.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):129-144. doi: 10.1111/jdv.14517. Epub 2017 Sep 12. Review.

PMID:
28796920
35.

Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease.

Bonanad C, González-Parra E, Rivera R, Carrascosa JM, Daudén E, Olveira A, Botella-Estrada R.

Actas Dermosifiliogr. 2017 Nov;108(9):800-808. doi: 10.1016/j.ad.2016.12.023. Epub 2017 Jun 11. Review. English, Spanish.

PMID:
28610662
36.

No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.

Rodríguez-Jiménez P, Chicharro P, Godoy A, Llamas-Velasco M, García M, Daudén E.

Br J Dermatol. 2017 Sep;177(3):862-863. doi: 10.1111/bjd.15654. Epub 2017 Jul 19. No abstract available.

PMID:
28508387
37.

Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.

Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, García-Doval I, Descalzo MA; Biobadaderm Study Group.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1700-1708. doi: 10.1111/jdv.14314. Epub 2017 Jun 6.

PMID:
28485816
38.

Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis.

Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Belmonte C, Cabaleiro T, Román M, Ochoa D, Talegón M, Saiz-Rodríguez M, Daudén E, Abad-Santos F.

Pharmacogenomics. 2017 May;18(7):631-638. doi: 10.2217/pgs-2017-0014. Epub 2017 May 4.

PMID:
28470127
39.

Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.

Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22. Review.

PMID:
28419600
40.

Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event.

Sanz-Navarro J, Feal C, Dauden E.

Actas Dermosifiliogr. 2017 Sep;108(7):643-649. doi: 10.1016/j.ad.2017.02.011. Epub 2017 Apr 3. English, Spanish.

PMID:
28385424
41.

Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis.

Ovejero-Benito MC, Cabaleiro T, Sanz-García A, Llamas-Velasco M, Saiz-Rodríguez M, Prieto-Pérez R, Talegón M, Román M, Ochoa D, Reolid A, Daudén E, Abad-Santos F.

Br J Dermatol. 2018 Mar;178(3):798-800. doi: 10.1111/bjd.15504. Epub 2018 Jan 28. No abstract available.

PMID:
28369750
42.

Psoriasis and Nonalcoholic Fatty Liver Disease.

Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A; en nombre del Grupo de Trabajo en Inflamación Sistémica en Psoriasis.

Actas Dermosifiliogr. 2017 Jul - Aug;108(6):506-514. doi: 10.1016/j.ad.2016.12.017. Epub 2017 Mar 16. Review. English, Spanish.

PMID:
28318525
43.

Induction of Autoantibodies and Autoimmune Diseases in Patients with Psoriasis Receiving Tumor Necrosis Factor Inhibitors.

Oter-López B, Llamas-Velasco M, Sánchez-Pérez J, Dauden E.

Actas Dermosifiliogr. 2017 Jun;108(5):445-456. doi: 10.1016/j.ad.2016.12.014. Epub 2017 Mar 6. English, Spanish.

PMID:
28267955
44.

Atypical Ulcerated Lesions in a Patient With Cogan Syndrome.

Solano-López G, Montes-Torres A, Tomero E, Fraga J, De Argila D, Daudén E.

Actas Dermosifiliogr. 2017 May;108(4):369-371. doi: 10.1016/j.ad.2016.10.017. Epub 2017 Feb 1. English, Spanish. No abstract available.

PMID:
28160939
45.

Nodular mucinosis associated with light-chain monoclonal gammopathy of uncertain significance.

Rodríguez-Jiménez P, Chicharro P, Ascensión A, de Argila D, Daudén E.

Actas Dermosifiliogr. 2017 Apr;108(3):272-273. doi: 10.1016/j.ad.2016.09.015. Epub 2016 Dec 13. English, Spanish. No abstract available.

PMID:
27979308
46.

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.

Prieto-Pérez R, Llamas-Velasco M, Cabaleiro T, Solano-López G, Márquez B, Román M, Ochoa D, Talegón M, Daudén E, Abad-Santos F.

Pharmacogenomics. 2017 Jan;18(2):157-164. doi: 10.2217/pgs-2016-0122. Epub 2016 Dec 15.

PMID:
27977334
47.

Combination therapy of infliximab and ciclosporin in the treatment of recalcitrant psoriasis: a case series.

Martinez-Mera C, Camarero-Mulas C, Sanz-Sánchez T, Daudén E.

Br J Dermatol. 2017 Mar;176(3):803-805. doi: 10.1111/bjd.15229. Epub 2017 Feb 7. No abstract available.

PMID:
27943238
48.

Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries.

Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ, Daudén E, Dam TN, Baker C, Spuls PI, Stern RS, Cohen AD.

Acta Derm Venereol. 2017 Apr 6;97(4):516-518. doi: 10.2340/00015555-2586. No abstract available.

49.

Prevalence of amyloid deposits determined by fine-needle aspiration of abdominal fat in patients with psoriasis.

Chicharro P, García-Río I, Rodríguez-Jiménez P, Pérez-Plaza A, Pérez-Gala S, Marrón C, Daudén E.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):e280-e281. doi: 10.1111/jdv.14038. Epub 2016 Nov 22. No abstract available.

PMID:
27878875
50.

Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.

Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group.

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1942-1950. doi: 10.1111/jdv.13682. Epub 2016 Jun 22.

PMID:
27329511

Supplemental Content

Loading ...
Support Center